Ye et al. [175] developed a monoclonal antibody (YW327.6S2) against Axl, which recognizes the receptor with high affinity, diminishing xenograft tumor growth and potentiating the effect of anti-VEGF treatment [175]. This evidence concerns the gene AXL and neoplasm.